Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) is a biopharmaceutical company that focuses on discovering, developing and commercializing novel medicines to address unmet medical needs. The company aims to improve the lives of patients through its innovative drug candidates that are designed to target specific diseases and conditions. It has a product to treat heart failure and Type-1 diabetes that has completed phase 3 trials. It also has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc.
Comps: Mersana Therapeutics, Inc. (Nasdaq:MRSN), Erasca, Inc. (Nasdaq:ERAS)
Before we compare, it is important to establish that these pharmaceutical companies all recorded negative earnings. As for relative metrics, Lexicon Pharmaceuticals still displayed a more favorable earnings per share and net loss than its counterparts. Not to mention, there is growth on the horizon with there drug awaiting registration and FDA approval.